Association of opioid use disorder with healthcare utilization and cost in a public health system.


Journal

Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118

Informations de publication

Date de publication:
11 2022
Historique:
received: 05 10 2021
accepted: 01 05 2022
pubmed: 1 6 2022
medline: 5 10 2022
entrez: 31 5 2022
Statut: ppublish

Résumé

To quantify the healthcare costs associated with opioid use disorder among members in a public healthcare system and compare them with healthcare costs in the general population. Retrospective cohort study. Inpatient and outpatient care settings of Israel's largest public healthcare provider (that covers 4.7 million members). Participants included 1173 members who had a diagnosis of opioid use disorder in the years between 2013 and 2018. Each patient was matched with 10 controls based on age and sex. The main outcome was monthly healthcare costs. The mean monthly healthcare cost of members with opioid use disorder was $1102 compared with $211 among controls (5.2-fold difference; 95% CI, 4.6-6.0). After excluding members with heroin related diagnoses before the index date (to focus on prescription opioids), this healthcare cost ratio did not substantially change (4.6-fold; 95% CI, 3.9-5.4). Members with opioid use disorder under the age of 65 years had a cost difference of 6.1-fold (95% CI, 5.2-7.1), whereas those 65 years and older experienced cost difference of 3.4-fold (95% CI, 2.6-4.5), compared with controls. The category with the highest cost for members with opioid use disorder was inpatient services, which was 8.7-fold (95%CI, 7.2-10.4) greater than among controls. Healthcare costs among individuals with opioid use disorder in Israel's public health system are substantially higher than among controls, at least partially attributable to prescription opioid use disorder. Differences are greater among individuals under 65 years.

Identifiants

pubmed: 35638374
doi: 10.1111/add.15963
pmc: PMC9796021
doi:

Substances chimiques

Analgesics, Opioid 0
Heroin 70D95007SX

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2880-2886

Informations de copyright

© 2022 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.

Références

MMWR Morb Mortal Wkly Rep. 2016 Jan 01;64(50-51):1378-82
pubmed: 26720857
Addiction. 2022 Nov;117(11):2880-2886
pubmed: 35638374
J Subst Abuse Treat. 2016 Aug;67:9-14
pubmed: 27296656
Drug Alcohol Depend. 2021 Apr 1;221:108583
pubmed: 33662670
Drug Alcohol Depend. 2020 Dec 1;217:108382
pubmed: 33183909
Addiction. 2020 Aug;115(8):1482-1493
pubmed: 31899565
Pain Pract. 2014 Mar;14(3):E116-25
pubmed: 24268019
Pediatrics. 2017 Apr;139(4):
pubmed: 28320868
Reg Anesth Pain Med. 2021 May;46(5):455-456
pubmed: 33214218
Drug Alcohol Depend. 2010 Oct 1;111(3):235-40
pubmed: 20627427
Addiction. 2002 Sep;97(9):1145-53
pubmed: 12199830
Clinicoecon Outcomes Res. 2015 Sep 15;7:477-88
pubmed: 26396536
Addiction. 2003 Aug;98(8):1129-35
pubmed: 12873247
Lancet. 2019 Oct 26;394(10208):1560-1579
pubmed: 31657732
Addiction. 2021 Dec;116(12):3482-3493
pubmed: 34170044
Pharmacoepidemiol Drug Saf. 2018 May;27(5):535-540
pubmed: 29488288
BMC Med. 2018 May 16;16(1):69
pubmed: 29764482
Addiction. 2008 Dec;103(12):1996-2005
pubmed: 18855809
Drug Alcohol Depend. 2021 Apr 1;221:108568
pubmed: 33578297
J Manag Care Pharm. 2005 Jul-Aug;11(6):469-79
pubmed: 15998164
Am J Health Econ. 2018 Summer;4(3):383-410
pubmed: 30498764
Anesthesiology. 2010 Jan;112(1):226-38
pubmed: 20010421
Addiction. 2021 Jun;116(6):1304-1312
pubmed: 32869394
Drug Alcohol Depend. 2018 Nov 1;192:74-79
pubmed: 30243142

Auteurs

Oren Miron (O)

Clalit Research Institute, Clalit Health Services, Ramat Gan, Israel.
School of Public Health, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Noam Barda (N)

ARC Innovation Center, Sheba Medical Center, Ramat-Gan, Israel.
Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.

Ran Balicer (R)

Clalit Research Institute, Clalit Health Services, Ramat Gan, Israel.
School of Public Health, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Ariel Kor (A)

Israel Center on Addiction, Netanya, Israel.
Yale University School of Medicine, New Haven, CT, USA.

Shaul Lev-Ran (S)

Israel Center on Addiction, Netanya, Israel.
Department of Psychiatry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH